ONO-4059-10:Phase 3 study in patients with steroid-resistant pemphigus

ONO-4059-10:Multicenter, placebo-controlled, randomized, double-blind, Phase 3 study in patients with steroid-resistant pemphigus (BRILLIANT study)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031220043

Enrollment

Registered

2022-04-27

Start date

2022-08-15

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

steroid-resistant pemphigus

Interventions

ONO-4059 will be administered orally once daily after a meal.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with a diagnosis of pemphigus 2. Patients with a re-increase in the pemphigus disease area index (PDAI) score before oral corticosteroid tapering to 10mg/day of PSL equivalent

Exclusion criteria

Exclusion criteria: 1. Patients with an active infection 2. Patients with malignancy 3. Patients with past history of serious allergy or anaphylaxis

Design outcomes

Primary

Measure	Time frame
Efficacy	—

Secondary

Measure	Time frame
Efficacy, Safety, Exploratory objective	—

Contacts

Public ContactSupport Desk JP

Ono Pharmaceutical Co.,LTD.

clinical_trial@ono-pharma.com+81-120-278-120

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026